Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 12 clinical trials, of which 3 were completed, 6 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Cretostimogene Grenadenorepvec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Cretostimogene Grenadenorepvec is expected to reach an annual total of $23 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Cretostimogene Grenadenorepvec Overview

CG-0070 is under development for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer, metastatic bladder cancer and metastatic urothelial cancer. The drug candidate is administered intravesically and intratumoral routes. CG-0070 is the first armed oncolytic virus therapy. It is engineered to secrete GM-CSF, an immune-stimulating hormone, which also serves as the adjuvant in GVAX cancer immunotherapy platform. It was under development for ovarian cancer, glioblastoma multiforme, lung cancer and head and neck cancer and other solid tumors.

Kissei Pharmaceutical Overview

Kissei Pharmaceutical (Kissei) is a pharmaceutical company. The company’s product portfolio includes medicines for urological, metabolic, endocrinological, obstetrics and gynecological, nephrological, ophthalmic, and pulmonary system disorders. The company sells protein-controlled foods, foods for the elderly and people receiving nursing care and energy supply foods. It also provides manufacturing and selling of noodle products, system integration and resource services, general construction and building management, information gathering and development support services. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto-Shi, Nagano, Japan.
The company reported revenues of (Yen) JPY75,579 million for the fiscal year ended March 2024 (FY2024), an increase of 12% over FY2023. The operating profit of the company was JPY4,322 million in FY2024, compared to an operating loss of JPY1,063 million in FY2023. In FY2024, the company recorded a net margin of 14.8%, compared to a net margin of 15.6% in FY2023. The company reported revenues of JPY21,164 million for the first quarter ended June 2024, an increase of 19.4% over the previous quarter.

For a complete picture of Cretostimogene Grenadenorepvec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 11 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.